Clinical trials: Stage IA NSCLC
Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer
Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
This research trial studies biomarkers in predicting treatment response in samples from patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy.
- Conditions
- Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer
- Trial name
- NCT01595074
- Testing
- medical chart review, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 950 people
- Sponsor
- National Cancer Institute (NCI)
Stage IA Non-small Cell Lung Cancer, Adenocarcinoma of the Lung
Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
The purpose of this study is to compare early-stage peripheral non-small cell lung cancer lobectomy and sub-lobectomy surgery to evaluate if sub-lobectomy is as feasible and effective for the treatment of early-stage (diameter…
- Conditions
- Stage IA Non-small Cell Lung Cancer, Adenocarcinoma of the Lung, Squamous Cell Lung Cancer
- Trial name
- NCT02288026
- Where
- China
- Volunteers
- 630 people
- Sponsor
- Capital Medical University
Lung Cancer
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be removed.
- Trial name
- NCT00104728
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lung Cancer
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
RATIONALE: Wedge resection or segmentectomy may be less invasive types of surgery than lobectomy for non-small cell lung cancer and may have fewer side effects and improve recovery.
- Trial name
- NCT00499330
- Testing
- lobectomy, segmentectomy or wedge resection
- Where
- 386 sites in United States, Australia and 1 more
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Neoplasms, Lymph Node Excision
Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
Lung cancer is the leading cause of cancer related death worldwide. Lobectomy or sub-lobectomy with mediastinal lymph node dissection is the standard surgery. About 50% lung nodules are pure ground-glass or part-solid nodules.
- Trial name
- NCT04631770
- Testing
- Systemic mediastinal lymph node dissection, Spared mediastinal lymph node dissection
- Where
- China
- Volunteers
- 1,362 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital